Cambridge Cognition announced Stuart Gall, Nick Rodgers, and Jon Kempster to join its Board as Independent Directors

– UK, Bottisham –  Cambridge Cognition Holdings plc (LON: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announced the appointments of Stuart Gall, Nick Rodgers, and Jon Kempster to its Board as Independent Directors at the end of Q3 2024.

Debra Leeves and Richard Bungay will stand down from the Board on 31 December 2025.

Finally, Dr. Steven Powell, Chair, who has previously served the Company as an Executive Director since 2015 and as Non-Executive Chair since 2019, will not stand for re-election at the 2026 AGM.

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise, we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

  • Clinical Studies for new pharmaceuticals;
  • Academic Research for scientists to understand CNS disorders;
  • Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
  • Consumer Health & Wellness is to provide individuals with access to accurate, reliable, and meaningful data to assess their cognitive health.

For more information: https://cambridgecognition.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.